Bridge Biotherapeutics enrols all subjects in idiopathic pulmonary fibrosis drug trial

Bridge Biotherapeutics has completed enrollment for a Phase II trial of BBT-877, an autotoxin inhibitor for idiopathic pulmonary fibrosis. The study aims to evaluate efficacy, safety, and tolerability, with results expected in the first half of next year.